Yesterday, the Mars rover Perseverance landed successfully on Mars — further pushing space technology to its limits and ushering in a new mission for space exploration. Back here on Earth, your editors had some new picks with big potential. And...
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Our latest trade has rocketed higher and higher from when we bought it in January. And considering just how fast this stock has surged, I think it makes sense to take some profits off the table.
We’ve spent billions on Alzheimer’s research, with nothing to show for it but a handful of drugs that don’t really change its course once it sets in. Hundreds of programs have failed this century. Now, one Biotech may be on a breakthrough that could be the cure we’ve been waiting for…
We pull back the curtain on a stock that’s ramping up the innovation curve so that you can act before mainstream investors are paying attention. This month, I want to show you a technology-packed electric vehicle company that you can buy before it goes pubic…
It was a very BIG new year’s day welcome it was for cannabis in Illinois with hundreds lining up to be among the first to legally purchase marijuana. Today Ray will cover the 2020 market and legal outlook for cannabis, both in the U.S. and Canada. Plus we’ll talk about how our current Mastermind plays will shape up with all the legal talk in place.
Prescription and illicit opiates are killing Americans by the tens of thousands every year. In 12 states today, there are more active opioid prescriptions than people. There’s no quick fix to the opioid crisis. But cannabis might provide a new tool for fighting it…
Before too long, we could have working vaccines and better therapeutics, easing fears of a potential second wave of COVID-19 infections later this year. The market really likes the thought of that! Biotech companies are trying to advance therapies in other diseases, of course, although things have been disrupted by COVID-19. It’s made it hard to recruit patients and run clinical trials, with some companies managing better than others…